Robotic surgeons and AI specialists have transitioned from research labs to operating rooms as cancer therapy with new technologies has become a realistic good.
Cancer diagnosis and treatment are being revolutionised by AI and robotics. Robots and artificial intelligence (AI) are healing disease and saving lives as a result of technology advancements that are altering the global healthcare industry.
Research institutions, non-profit organisations, and academic institutions are increasingly working with private enterprises of all sizes in order to get these unique products on the market as fast as feasible.
Lunit, an AI company with headquarters in Seoul, worked with Fujifilm to enhance Lunit’s chest X-ray software, Lunit INSIGHT CXR. The company also sells Lunit INSIGHT MMG, an AI solution for mammography, and Lunit SCOPE, an AI solution for oncology therapy.
“Artificial intelligence is quickly advancing cancer research, and it’s exciting to see the excellent progress Lunit has made in developing state-of-the-art AI-powered radiology and pathology solutions that have the potential to significantly improve cancer diagnosis and treatment,” says Helmy Eltoukhy, CEO of Guardant Health.
Johnson & Johnson’s Lung Cancer Initiative and lung health speciality company Optellum deliberately worked together last year to increase lung cancer survival rates. As part of the deal, Optellum will help early detection and prevention of lung cancer using its AI-powered clinical decision support platform.
The fusion of cutting-edge new technologies will be the next step in the detection and treatment of lung cancer, according to Professor Sam Janes, MD, Head of the Respiratory Research Department at UCL Hospitals, Vice-Chair of the UK National Clinical Reference Group for Lung Cancer, and member of the Optellum Medical Advisory Board. AI is crucial for integrating imaging, clinical, and genetic data, such as that from liquid biopsies, and for earlier illness diagnosis. These two technologies working together could greatly enhance medical personnel’ capacity to identify, care for, and eventually prevent persons with early-stage lung cancer.
AI uses iToBoS and V7 to tackle cancer.
Last month, an article in AI Magazine featured the iToBoS group. The EU’s Horizon 2020 initiative provided cash for them to develop a computer that would scan people and thoroughly examine moles to seek for anything that would be dangerous to health, such malignant melanoma.
“Visiting the dermatologist now requires them to physically put a dermoscopy on each lesion to take an image, which is both time-intensive and error-prone,” claims Alberto Rizzoli, CEO and Co-Founder of consortium member V7. With the help of iToBos, we can keep track of past scans and compare the precise location of a lesion that has already been identified to determine whether its look has changed, posing a potential problem, or whether a new one has appeared.
And now, a brand-new study led by professionals at The Royal Marsden NHS Foundation Trust shows that using robots to perform the cutting-edge surgical procedure known as Trans-Oral Robotic Surgery (TORS), patients with head and neck cancer have a higher chance of survival and experience quicker recovery times.
Transoral Robotic Surgery for Recurrent Tumors of the Upper Aerodigestive Tract (RECUT): An International Cohort Study was the headline of an article published in this month’s issue of the Journal of the National Cancer Institute.
TORS has improved two-year overall survival rates for patients with recurrent head and neck cancer to 72%, which is a significant improvement above currently available therapies for this particular population. According to past studies, the two-year survival rates for patients with recurrent head and neck cancer can be as low as 40%.
These positive results suggest that TORS offers durable survival for patients with recurrent head and neck cancer compared to current standard therapies, such as open surgery, says study leader Professor Vinidh Paleri, Consultant Head & Neck Surgeon at The Royal Marden NHS Foundation Trust.
Robots, AI, and cancer hospitals all have promising futures.
Robotics and software are fast revolutionising healthcare, and this change is having a significant impact on the field of medicine, according to Dr. Antonio Espingardeiro, an IEEE member and specialist in both fields. Additionally, AI and robotics have cemented their positions in the healthcare sector.
The potential for technology in the medical sector, according to him, is enormous as artificial intelligence develops and becomes more effective at performing tasks that have historically been performed by people.
Espingardeiro predicts that the surgical robots of the future will offer a great deal of novel value. Technology can relieve medical staff of mundane tasks and free up resources for more important tasks, resulting in safer and more affordable medical procedures for patients.
Robotic surgery can lead to significantly less invasive procedures and a decrease in tremor in humans, which lowers patient trauma and hastens recovery. Read More
